In January 2024, Pakistan is expected to receive 500,000 doses of Pfizer’s latest COVID-19 vaccine, model 2023-24.
The main aim is to vaccinate high-risk groups, especially those planning to participate in the Hajj pilgrimage. Before getting vaccinated, there is one important step to take.
Since the new Pfizer vaccine has been approved for exclusive emergency use by the US FDA, an emergency use authorization (EUA) from the Drug Regulatory Authority of Pakistan (DRAP) is required.
This advanced vaccine proves effective against many viruses, including Euromicron, With the number of COVID-19 infections increasing worldwide, especially with the emergence of the Omicron JN.1 sub-variant, authorities predict that this new vaccine will play a central role in reducing virus transmission, especially among travelers.
Despite the relatively low COVID-19 positivity rate in Pakistan, officials stress the importance of the new mRNA vaccine. It is hoped that Saudi officials will see this as a necessity for the region, especially as the Hajj season approaches.Notably, any vaccine approved for emergency use must comply with the DRAP certification process, according to FDA guidance.
Concerns have been raised about the vaccine’s suitability for children aged 6 months to 11 years.
Although its effectiveness is ongoing in this age group, the focus remains on determining susceptibility in adults, emphasizing a cautious approach to vaccination.
